醫院感染治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、應用、地區和競爭格局分類，2021-2031年

全球醫院感染治療市場預計將從 2025 年的 96.5 億美元成長到 2031 年的 136.5 億美元，複合年成長率為 5.95%。

此領域涵蓋用於控制患者住院期間發生的醫院感染的藥物製劑，例如抗生素、抗真菌藥物和抗病毒藥物。市場擴張的主要促進因素是多重抗藥性病原體的傳播以及全球人口老化趨勢。因此，需要長期住院和複雜侵入性手術的病例數量增加。此外，臨床上對敗血症和導管相關併發症的認知不斷提高，促使醫療機構實施先進的抗菌通訊協定，從而確保了對有效治療性介入的持續需求。

另一方面，市場成長的一大障礙是新藥研發缺乏經濟可行性。這導致新療法嚴重短缺。除了龐大的研發成本外，短期療法的低投資報酬率也阻礙了永續的商業性合作。根據國際藥品製造商協會聯合會（IFPMA）2024年的數據，只有一種抗生素候選藥物處於針對四種高優先級細菌病原體的III期臨床試驗階段。後期候選藥物的匱乏凸顯了目前阻礙產業創新的巨大資金障礙。

市場促進因素

多重抗藥性病原體的傳播是推動全球醫院感染治療市場發展的主要動力。隨著細菌發展出複雜的抗藥性機制，標準抗生素治療的療效持續下降，因此亟需引進先進的最後防線療法。醫院感染，尤其是加護病房（ICU）感染的日益增多，進一步加劇了這一需求，因為ICU中的脆弱患者面臨更高的感染風險。 2024年5月，世界衛生組織（WHO）在其「2024年細菌病原體優先清單」中，將15種抗藥性細菌列為新藥研發的首要目標。此外，2024 年 7 月，美國疾病管制與預防中心 (CDC) 在其「2021-2022 年美國抗菌素抗藥性威脅」分析中報告稱，COVID-19 大流行期間醫院獲得性抗菌素抗藥性感染疾病比大流行前水準增加了 20%，這凸顯了繼續採取有效醫療干預措施的必要性。

同時，支持性的法規結構和政府資金在維持市場發展勢頭方面發揮著至關重要的作用，它們能夠降低抗菌藥物研發過程中面臨的高風險。由於短效抗生素的商業性回報往往不足以吸引私人資本，公共部門的投資對於維持強大的臨床研發管線至關重要。各國政府和國際組織正擴大利用激勵獎勵來支持生技公司進行成本高昂的早期研發工作。例如，2024年5月，英國衛生和社會保障部撥款8,500萬英鎊，作為「2024-2029年抗菌素抗藥性國家行動計畫」的一部分，用於支持國際合作和舉措舉措，以對抗抗菌素抗藥性。這筆未稀釋的資金將降低製藥公司在研發過程中的風險，並確保有穩定的新療法候選藥物進入市場，用於應對危機。

市場挑戰

全球醫院感染治療市場面臨的最大障礙是新型抗菌藥物研發缺乏經濟可行性。這種結構性市場失靈源自於研發投入龐大，卻無法產生足夠的效益來彌補高成本。主要原因是，新型抗生素通常作為防止抗藥性產生的最後手段，而非大規模上市。這種不利的經濟環境阻礙了製藥公司維持其抗菌藥物產品組合，導致資本剝離和研發管線停滯。因此，難以生產市場強勁成長所需的高附加價值產品。

這些創新治療方法的供應中斷迫使市場依賴價格較低的學名藥，而非昂貴的新療法，直接限制了市場擴張。國際藥品製造商協會聯合會（IFPMA）2024年報告指出，這些與獎勵相關的挑戰導致2017年至2023年間僅有10種新抗生素獲得監管機構的核准，其中只有兩種被認定為創新療法。新療法的產量如此之低，嚴重限制了商機，並阻礙了市場滿足不斷變化的醫療需求的能力。

市場趨勢

人工智慧驅動的藥物發現正在從根本上重塑全球醫院感染治療市場，它加速了新型抗菌化合物的發現，而這些化合物往往被傳統篩檢方法所忽略。這項技術使製藥公司能夠快速分析龐大的化合物庫，並預測其對抗藥性菌株的分子水平療效，從而重振停滯的臨床試驗項目。透過利用機器學習演算法，研發人員可以以前所未有的速度最佳化兼具安全性和有效性的先導化合物，直接解決醫院感染有效治療方法嚴重短缺的問題。矽谷評論（The Silicon Review）在2025年3月發表了報導，強調了這一趨勢。文章指出，輝瑞正在投資20億美元開發一個由人工智慧驅動的藥物發現平台，旨在自動識別針對多重抗藥性病原體的下一代治療方法。

同時，噬菌體療法正迅速崛起，成為傳統抗生素的極具前景的替代方案。由於細菌抗藥性機制導致標準藥物療效不佳，治療重點正轉向噬菌體（一種特異性靶向併中和致病菌，同時不損害有益微生物群或誘導廣譜抗藥性的病毒）。這一趨勢標誌著模式轉移生物干預，為菌血症和導管相關感染疾病等難治性疾病提供了精準的治療選擇。根據Armata Pharmaceuticals公司於2025年11月發布的2025年第三季財報，其旗艦噬菌體候選藥物AP-SA02在複雜性金黃色葡萄球菌感染患者中實現了100%的無復發臨床緩解率，充分展現了這些新型生物製藥的巨大治療潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫院感染治療市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（抗生素、抗真菌藥物、抗病毒藥物、其他）
  • 依應用領域（血液感染疾病、肺炎、手術部位感染疾病、尿道感染、胃腸道疾病和其他院內感染疾病）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美醫院感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲醫院感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區醫院感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲醫院感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲醫院感染治療市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球醫院感染治療市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Allergan Plc.
• AstraZeneca Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Hospital Infection Therapeutics Market is projected to expand from USD 9.65 Billion in 2025 to USD 13.65 Billion by 2031, progressing at a CAGR of 5.95%. This sector comprises pharmaceutical formulations, including antibiotics, antifungals, and antivirals, utilized to combat nosocomial infections contracted by patients during hospital stays. Market expansion is primarily driven by the growing prevalence of multidrug-resistant pathogens and a global demographic shift towards an aging population, which necessitates extended hospitalizations and complex invasive procedures. Additionally, heightened clinical awareness regarding sepsis and catheter-related complications obliges healthcare facilities to implement advanced antimicrobial protocols, thereby ensuring a sustained demand for effective therapeutic interventions.

Conversely, a substantial hurdle impeding market growth is the lack of economic feasibility in developing novel drugs, resulting in a critical shortage of new treatment options. The exorbitant costs of research, combined with minimal returns on investment for short-course therapies, deter sustained commercial engagement. Data from the International Federation of Pharmaceutical Manufacturers and Associations in 2024 indicated that there was merely one antibiotic candidate in Phase III clinical trials addressing the four bacterial pathogens deemed critical priorities. This scarcity of late-stage candidates highlights the significant financial barriers that currently suppress innovation within the industry.

Market Driver

The rising prevalence of multidrug-resistant pathogens acts as the primary engine driving the Global Hospital Infection Therapeutics Market. As bacteria develop sophisticated resistance mechanisms, standard antibiotic treatments are becoming increasingly ineffective, compelling the adoption of advanced, reserve-line therapeutics. This necessity is intensified by the growing incidence of hospital-acquired infections, particularly within intensive care units where vulnerable patients face elevated risks. In May 2024, the World Health Organization's 'WHO Bacterial Priority Pathogens List 2024' identified 15 families of antibiotic-resistant bacteria as critical priorities for new drug development. Furthermore, the Centers for Disease Control and Prevention reported in July 2024, within its 'Antimicrobial Resistance Threats in the United States, 2021-2022' analysis, that hospital-onset antimicrobial-resistant infections rose by 20% during the COVID-19 pandemic compared to pre-pandemic levels, demonstrating the persistent need for effective medical interventions.

Concurrently, supportive regulatory frameworks and government funding play a vital role in sustaining market momentum by mitigating the high risks associated with antimicrobial drug development. Since the commercial return on short-course antibiotics is often insufficient to attract private equity, public sector investment has become essential for maintaining a robust clinical pipeline. Governments and international organizations are increasingly utilizing push incentives to assist biotech companies through the expensive early stages of research. For instance, the UK Department of Health and Social Care committed £85 million in May 2024, as part of its 'Confronting antimicrobial resistance 2024 to 2029' national action plan, to support global partnerships and research initiatives against antimicrobial resistance. This provision of non-dilutive capital de-risks the development process for pharmaceutical firms, ensuring a consistent flow of novel therapeutic candidates entering the market to address the crisis.

Market Challenge

The most significant obstacle facing the Global Hospital Infection Therapeutics Market is the lack of economic viability in developing novel antimicrobial agents. This structural market failure arises because the high costs associated with research and development are not matched by adequate returns on investment, largely because new antibiotics are typically reserved as last-resort treatments to prevent resistance rather than being sold in high volumes. This adverse economic environment discourages pharmaceutical companies from maintaining their antimicrobial portfolios, leading to a withdrawal of capital and a stagnant pipeline that fails to produce the high-value products necessary for robust market growth.

This disruption in the supply of innovative treatments directly constrains financial expansion by forcing the market to rely on older, lower-cost generics rather than premium novel therapies. A 2024 report by the International Federation of Pharmaceutical Manufacturers and Associations highlighted that, due to these incentive-related challenges, only ten new antibiotics were approved by stringent regulatory authorities between 2017 and 2023, with just two classified as innovative. This minimal output of novel therapeutics severely limits revenue opportunities and inhibits the market's ability to address evolving medical needs.

Market Trends

The integration of AI-driven drug discovery is fundamentally reshaping the Global Hospital Infection Therapeutics Market by accelerating the identification of novel antimicrobial compounds that traditional screening methods often miss. This technological incorporation allows pharmaceutical companies to rapidly analyze vast chemical libraries and predict molecular efficacy against resistant bacterial strains, thereby revitalizing a stagnant clinical pipeline. By utilizing machine learning algorithms, developers can optimize lead candidates for safety and potency at unprecedented speeds, directly addressing the critical shortage of effective treatments for hospital-acquired infections. Highlighting this trend, The Silicon Review reported in March 2025, in an article titled 'Pfizer's $2B AI-Powered Antibiotics to Combat Superbugs', that Pfizer has committed $2 billion to an AI-powered discovery platform specifically designed to automate the identification of next-generation treatments for multidrug-resistant pathogens.

Simultaneously, the market is witnessing the significant emergence of phage therapy as a credible alternative to conventional antibiotics. As bacterial resistance mechanisms compromise standard drug classes, therapeutic focus is shifting toward bacteriophages-viruses that specifically target and neutralize pathogenic bacteria without harming beneficial microbiota or inducing broad-spectrum resistance. This trend represents a paradigm shift from chemical to biological interventions, offering precision treatment options for difficult-to-treat conditions like bacteremia and catheter-associated infections. According to the 'Third Quarter 2025 Results' report from Armata Pharmaceuticals in November 2025, the company's lead phage candidate, AP-SA02, achieved a 100% clinical response rate without relapse in patients with complicated Staphylococcus aureus bacteremia, underscoring the high therapeutic potential of these novel biological agents.

Key Market Players

• Merck & Co., Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company, Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd
• Allergan Plc.
• AstraZeneca Plc.

Report Scope

In this report, the Global Hospital Infection Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hospital Infection Therapeutics Market, By Drug Type

• Antibiotics Drugs
• Antifungal Drugs
• Antiviral Drugs
• Others

Hospital Infection Therapeutics Market, By Application

• Bloodstream Infections
• Pneumonia
• Surgical Site Infections
• Urinary Tract Infections
• Gastrointestinal Disorders
• Other Hospital Infections

Hospital Infection Therapeutics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hospital Infection Therapeutics Market.

Available Customizations:

Global Hospital Infection Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hospital Infection Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Antibiotics Drugs, Antifungal Drugs, Antiviral Drugs, Others)
  • 5.2.2. By Application (Bloodstream Infections, Pneumonia, Surgical Site Infections, Urinary Tract Infections, Gastrointestinal Disorders, Other Hospital Infections)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Hospital Infection Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hospital Infection Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Hospital Infection Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Hospital Infection Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application

7. Europe Hospital Infection Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hospital Infection Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Hospital Infection Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Hospital Infection Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Hospital Infection Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Hospital Infection Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Hospital Infection Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hospital Infection Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Hospital Infection Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Hospital Infection Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Hospital Infection Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Hospital Infection Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Hospital Infection Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hospital Infection Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Hospital Infection Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Hospital Infection Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application

10. South America Hospital Infection Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hospital Infection Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Hospital Infection Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Hospital Infection Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hospital Infection Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck & Co., Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Bayer AG
• 15.4. GlaxoSmithKline Plc.
• 15.5. Daiichi Sankyo Company, Limited
• 15.6. AbbVie Inc.
• 15.7. Abbott Laboratories
• 15.8. F. Hoffmann-La Roche Ltd
• 15.9. Allergan Plc.
• 15.10. AstraZeneca Plc.

16. Strategic Recommendations

17. About Us & Disclaimer